I've owned quite a few biotechs over the years, but Lexicon Pharmaceuticals (LXRX)
is maybe one of the most frustrating I've owned. Forget about the
company's prior business model of selling gene knockout data to drug
developers and its near-death experience about five years ago - the
simple fact that the company has some very interesting clinical
candidates but can't get much love or attention from prospective
partners is plenty frustrating in its own right.
Well, here we go
again. Lexicon announced very encouraging data on its lead compound for
diabetes ('4211), with the company's proprietary SGLT 1/2 inhibitor
showing solid glucose control in diabetes patients with significant
renal impairment. I don't really think this study is surprising to
Lexicon bulls, but the Street is clearly cheered by the news and I
suspect part of that enthusiasm is the hope/expectation that the last
real obstacle to a partnership agreement may now be in the past.
Please read more here (subscription required for the first 24 hours):
Will More Good Data From Lexicon Finally Bring In A Partner?
No comments:
Post a Comment